Robust evidence from high-quality research is vital for pandemic and epidemic intelligence, forming the basis for effective collaborative surveillance and informed public health decisions. The COVID-19 pandemic has spurred innovation in data and laboratory science and improved our ability to detect, assess and respond to health threats. However, research on surveillance methods and tools requires greater coherence and more efficient ways to translate research for evidence-based policy-making. The WHO Pandemic Hub has coordinated a process to set research priorities that should be particularly relevant for routine public health surveillance practices in collaboration with the Global Research Collaboration for Infectious Disease Preparedness (GloPID-R), Charité University Hospital Berlin and the WHO Science Division and with a financial contribution and observer role of Wellcome Trust. The goal was to identify the key research areas that would generate high-quality evidence and methods to better inform decision-making in global health emergencies. This technical brief outlines the priorities for research in pandemic and epidemic intelligence identified through the prioritization process.

A NEW AND ESSENTIAL RESOURCE FOR THE PRACTICE OF EPIDEMIOLOGY AND PUBLIC HEALTH The CDC Field Epidemiology Manual is a definitive guide to investigating acute public health events on the ground and in real time. Assembled and written by experts from the Centers for Disease Control and Prevention as well as other leading public health agencies, it offers current and field-tested guidance for every stage of an outbreak investigation -- from identification to intervention and other core considerations along the way. Modeled after Michael Gregg's seminal book Field Epidemiology, this CDC manual ushers investigators through the core elements of field work, including many of the challenges inherent to outbreaks: working with multiple state and federal agencies or multinational organizations; legal considerations; and effective utilization of an incident-management approach. Additional coverage includes: � Updated guidance for new tools in field investigations, including the latest technologies for data collection and incorporating data from geographic information systems (GIS) � Tips for investigations in unique settings, including healthcare and community-congregate sites � Advice for responding to different types of outbreaks, including acute enteric disease; suspected biologic or toxic agents; and outbreaks of violence, suicide, and other forms of injury For the ever-changing public health landscape, The CDC Field Epidemiology Manual offers a new, authoritative resource for effective outbreak response to acute and emerging threats. *** Oxford University Press will donate a portion of the proceeds from this book to the CDC Foundation, an independent nonprofit and the sole entity created by Congress to mobilize philanthropic and private-sector resources to support the Centers for Disease Control and Prevention's critical health protection work. To learn more about the CDC Foundation, visit www.cdcfoundation.org.

The emergence of severe acute respiratory syndrome (SARS) in late 2002 and 2003 challenged the global public health community to confront a novel epidemic that spread rapidly from its origins in southern China until it had reached more than 25 other countries within a matter of months. In addition to the number of patients infected with the SARS virus, the disease had profound economic and political repercussions in many of the affected regions. Recent reports of isolated new SARS cases and a fear that the disease could reemerge and spread have put public health officials on high alert for any indications of possible new outbreaks. This report examines the response to SARS by public health systems in individual countries, the biology of the SARS coronavirus and related coronaviruses in animals, the economic and political fallout of the SARS epidemic, quarantine law and other public health measures that apply to combating infectious diseases, and the role of international organizations and scientific cooperation in halting the spread of SARS. The report provides an illuminating survey of findings from the epidemic, along with an assessment of what might be needed in order to contain any future outbreaks of SARS or other emerging infections.

This book presents a compilation of the most recent implementation of artificial intelligence methods for solving different problems generated by the COVID-19. The problems addressed came from different fields and not only from medicine. The information contained in the book explores different areas of machine and deep learning, advanced image processing, computational intelligence, IoT, robotics and automation, optimization, mathematical modeling, neural networks, information technology, big data, data processing, data mining, and likewise. Moreover, the chapters include the theory and methodologies used to provide an overview of applying these tools to the useful contribution to help to face the emerging disaster. The book is primarily intended for researchers, decision makers, practitioners, and readers interested in these subject matters. The book is useful also as rich case studies and project proposals for postgraduate courses in those specializations.

Governments, businesses, and individuals around the world are thinking about what happens after the COVID-19 pandemic. Can we hope to not only ward off another COVID-like disaster but also eliminate all respiratory diseases, including the flu? Bill Gates, one of our greatest and most effective thinkers and activists, believes the answer is yes. The author of the #1 New York Times best seller How to Avoid a Climate Disaster lays out clearly and convincingly what the world should have learned from COVID-19 and what all of us can do to ward off another catastrophe like it. Relying on the shared knowledge of the world’s foremost experts and on his own experience of combating fatal diseases through the Gates Foundation, Gates first helps us understand the science of infectious diseases. Then he shows us how the nations of the world, working in conjunction with one another and with the private sector, how we can prevent a new pandemic from killing millions of people and devastating the global economy. Here is a clarion call—strong, comprehensive, and of the gravest importance.

This book presents a decade of advances in the psychological, biological and social responses to disasters, helping medics and leaders prepare and react.

The Forum on Emerging Infections was created in 1996 in response to a request from the Centers for Disease Control and Prevention and the National Institutes of Health. The goal of the forum is to provide structured opportunities for representatives from academia, industry, professional and interest groups, and government to examine and discuss scientific and policy issues that relate to research, prevention, detection, and management of emerging infectious diseases. A critical part of this mission has been the convening of a series of workshops. Public Health Systems and Emerging Infections summarizes the fourth in a series of five workshops. With a focus on our knowledge and understanding of the role of private and public health sectors in emerging infectious disease surveillance and response, the participants explored the effects of privatization of public health laboratories and the modernization of public health care. The issues discussed included epidemiological investigation, surveillance, communication, coordination, resource allocations, and economic support.

While much progress has been made on achieving the Millenium Development Goals over the last decade, the number and complexity of global health challenges has persisted. Growing forces for globalization have increased the interconnectedness of the world and our interdependency on other countries, economies, and cultures. Monumental growth in international travel and trade have brought improved access to goods and services for many, but also carry ongoing and ever-present threats of zoonotic spillover and infectious disease outbreaks that threaten all. Global Health and the Future Role of the United States identifies global health priorities in light of current and emerging world threats. This report assesses the current global health landscape and how challenges, actions, and players have evolved over the last decade across a wide range of issues, and provides recommendations on how to increase responsiveness, coordination, and efficiency â€" both within the U.S. government and across the global health field.

The GOARN 2022–2026 Strategy Implementation Plan is a derivative product which follows the GOARN 2022-2026 Strategy. The Implementation Plan is intended to define and present, in a systematic manner and in alignment with GOARN’s areas of work, how the Strategy will be implemented. The Implementation Plan outlines the activities which contribute to GOARN projects and areas of work, and provides timelines for how these will be implemented through to the end of the Strategy.

Drug overdose, driven largely by overdose related to the use of opioids, is now the leading cause of unintentional injury death in the United States. The ongoing opioid crisis lies at the intersection of two public health challenges: reducing the burden of suffering from pain and containing the rising toll of the harms that can arise from the use of opioid medications. Chronic pain and opioid use disorder both represent complex human conditions affecting millions of Americans and causing untold disability and loss of function. In the context of the growing opioid problem, the U.S. Food and Drug Administration (FDA) launched an Opioids Action Plan in early 2016. As part of this plan, the FDA asked the National Academies of Sciences, Engineering, and Medicine to convene a committee to update the state of the science on pain research, care, and education and to identify actions the FDA and others can take to respond to the opioid epidemic, with a particular focus on informing FDA's development of a formal method for incorporating individual and societal considerations into its risk-benefit framework for opioid approval and monitoring.